You just read:

Positive Phase 3 Results Presented for Dupixent® (dupilumab) Show Significant Improvement on Multiple Measures of Disease Severity in Adolescents with Moderate-to-Severe Atopic Dermatitis

News provided by

Regeneron Pharmaceuticals, Inc.

Sep 15, 2018, 01:59 ET